Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

墨西哥湾沿岸联盟 (GCC) 研究评估和商业化中心

• 批准号: 10783414
• 负责人: PETER J DAVIES
• 金额: $ 99.94万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-25 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10783414
• 关键词: Academic Training; Address; Admission activity; Agreement; Area; Award; Biological Sciences; Biomedical Research; Biomedical Technology; Biotechnology; Businesses; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Complex; Development; Ecosystem; Education; Educational Activities; Educational process of instructing; Eligibility Determination; Employment Opportunities; Ensure; Equilibrium; Evaluation Research; Face; Funding; Goals; Growth; Health; Health Professional; Health Sciences; Healthcare; Hospitals; Incubators; Infrastructure; Institution; Intellectual Property; Investments; Joints; Laboratories; Leadership; Legal; Link; Malignant Neoplasms; Marketing; Medical; Medical center; Medicine; Mentors; Mentorship; Methodist Church; Mission; Outcome; Participant; Patients; Personal Satisfaction; Pharmacologic Substance; Process; Records; Research; Research Institute; Research Personnel; Resources; Rice; Services; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Stream; Talents; Technology; Technology Transfer; Texas; Therapeutic; Time; Training; Training Programs; Translating; Trust; Underrepresented Populations; United States National Institutes of Health; Universities; Work; career networking; catalyst; college; commercialization; design; drug development; drug discovery; education resources; experience; gulf coast; improved; innovation; medical schools; member; novel; programs; research facility; success; technology development; timeline

In recent years, the NIH has awarded over $850M annually to the numerous research institutions and hospitals within the Texas Medical Center (TMC; Houston, TX), producing ever-increasing numbers of biomedical discov- eries. Despite this massive investment, only some of these discoveries advance to the clinic, and even fewer are successfully commercialized to improve patient health and well-being. Texas academic entrepreneurs face significant challenges as they seek to commercialize their discoveries, including a lack of training and resources to support early-stage business and technology development. To address these deficiencies, we will establish the Gulf Coast Consortium Research Evaluation and Commercialization Hub (GCC-REACH) as an inte- grated multi-institutional resource wherein nascent academic entrepreneurs work closely with successful life science experts and experienced biotech executives to develop strategic milestone-driven timelines to rapidly validate the commercial value of their discoveries. GCC-REACH will expand the GCC and TMC infrastructure and resources we have designed to support emerging biomedical companies. Academic entrepreneurs will hail from all GCC-affiliated institutions (Baylor College of Medicine, Texas A&M Health Science Center, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas Southern University, Univer- sity of Houston, the University of Texas Health Science Center, University of Texas Medical Branch), Houston- area colleges and universities with large historically-underrepresented groups, and other Texas research insti- tutions. The GCC-REACH program will provide managerial oversight, access to vetted resources, and seed funds to assist each entrepreneur in progressing to a clear value-added commercialization inflection point. Significance. Discussions with numerous Texas-based researchers, all GCC-affiliated technology transfer of- fices, successful life science companies, and healthcare investors have indicated widespread support for this initiative, noting that it would help launch new companies and advance biomedical discoveries. Importantly, GCC-REACH will pair entrepreneurs who balance full-time clinical, teaching, and laboratory duties with EIRs and expert teams who will provide mentorship and assistance in completing the market analysis, business plans, and technology development strategies. Value proposition. In combination with substantial multi-institutional support, NIH's $4M investment will enable GCC-REACH to train academic entrepreneurs to successfully commercialize novel discoveries. We expect these entrepreneurs will launch approximately 60 highly-competitive early-stage biomedical companies that will be highly competitive for non-dilutive NIH SBIR/STTR funding and venture investment.

近年来，NIH每年向众多研究机构和医院提供超过8.5亿美元的资助， 在得克萨斯州医学中心（TMC;休斯顿，得克萨斯州），生产越来越多的生物医学发现， eries。尽管投资如此巨大，但其中只有一些发现进入了临床，甚至更少 成功地商业化，以改善患者的健康和福祉。德州学术企业家面临 在他们寻求将其发现商业化时面临重大挑战，包括缺乏培训和资源 支持早期业务和技术开发。为了解决这些问题，我们将 Gulf Coast Consortium Research Evaluation and Commercialization Hub（GCC-REACH）是一个全球性的研究评估和商业化中心。 一个多机构的资源，其中新生的学术企业家密切合作，成功的生活 科学专家和经验丰富的生物技术高管制定战略里程碑驱动的时间表，以迅速 证明他们发现的商业价值。GCC-REACH将扩大GCC和TMC基础设施 和资源，以支持新兴的生物医药公司。学术型企业家会欢呼 来自所有GCC附属机构（贝勒医学院、德克萨斯A&M健康科学中心、休斯顿 卫理公会研究所，医学博士安德森癌症中心，莱斯大学，得克萨斯州南方大学，大学- 休斯顿市，德克萨斯大学健康科学中心，德克萨斯大学医学分支），休斯顿- 地区学院和大学与大型历史代表性不足的群体，和其他得克萨斯州的研究机构， 学费GCC-REACH计划将提供管理监督，获得审查资源和种子 基金，以协助每个企业家在进展到一个明确的增值商业化的拐点。 意义与许多德克萨斯州的研究人员进行了讨论，所有GCC附属的技术转让- 成功的生命科学公司和医疗保健投资者对此表示了广泛的支持 他指出，这将有助于创办新公司并推进生物医学发现。重要的是， GCC-REACH将为平衡全职临床，教学和实验室职责与EIR的企业家配对 以及专家团队，他们将在完成市场分析，商业计划， 技术发展战略。 价值主张。结合大量的多机构支持，NIH的400万美元投资将使 GCC-REACH培训学术企业家，成功地将新发现商业化。我们预计这些 企业家将推出约60家竞争激烈的早期生物医学公司，这些公司将 在非稀释性NIH SBIR/STTR资金和风险投资方面极具竞争力。